(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 27.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Verrica Pharmaceuticals's revenue in 2026 is $30,321,000.On average, 8 Wall Street analysts forecast VRCA's revenue for 2026 to be $443,796,758, with the lowest VRCA revenue forecast at $392,002,718, and the highest VRCA revenue forecast at $487,018,583. On average, 8 Wall Street analysts forecast VRCA's revenue for 2027 to be $709,020,035, with the lowest VRCA revenue forecast at $525,258,561, and the highest VRCA revenue forecast at $896,474,947.
In 2028, VRCA is forecast to generate $1,090,767,017 in revenue, with the lowest revenue forecast at $609,434,612 and the highest revenue forecast at $1,976,934,693.